Zhuangzhuang Zhang

Zhuangzhuang Zhang

Auto-generated profile, based on publicly available information

Zhuangzhuang Zhang

Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ZZZhuangzhuang Zhang
Zhuangzhuang Zhang
LCLijun Cheng
Lijun Cheng
JLJie Li
Jie Li
QQQi Qiao
Qi Qiao
AKAnju Karki
Anju Karki
XLXiaoqi Liu
Xiaoqi Liu
Polo-like kinase 1 (Plk1) plays an important role in cell-cycle regulation. Recent work has suggested that Plk1 could be a biomarker of gemcitabine response in pancreatic ductal adenocarcinoma (PDAC). Although targeting Plk1 to treat PDAC has been attempted in clinical trials, the results were not promising, and the mechanisms of resistance to Plk1 inhibition is poorly understood. In addition, the role of Plk1 in PDAC progression requires further elucidation. Here, we showed that Plk1 was associated with poor outcomes in patients with PDAC. In an inducible transgenic mouse line with specific expression of Plk1 in the pancreas, Plk1 overexpression significantly inhibited caerulein-induced acute pancreatitis and delayed development of acinar-to-ductal metaplasia and pancreatic intraepithelial neoplasia. Bioinformatics analyses identified the regulatory networks in which Plk1 is involved in PDAC disease progression, including multiple inflammation-related pathways. Unexpectedly, inhibition or depletion of Plk1 resulted in upregulation of PD-L1 via activation of the NF-κB pathway. Mechanistically, Plk1-mediated phosphorylation of RB at S758 inhibited the translocation of NF-κB to nucleus, inactivating the pathway. Inhibition of Plk1 sensitized PDAC to immune checkpoint blockade therapy through activation of an antitumor immune response. Together, Plk1 suppresses PDAC progression and inhibits NF-κB activity, and targeting Plk1 can potentiate the efficacy of immunotherapy in PDAC. Significance: Inhibition of Plk1 induces upregulation of PD-L1 expression in pancreatic ductal adenocarcinoma, stimulating antitumor immunity and sensitizing tumors to immunotherapy.

16 February 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
JWJiaoxiang Wu
Jiaoxiang Wu
KHKunyan He
Kunyan He
ZZZhuang-Zhuang Zhang
Zhuang-Zhuang Zhang
YQYu-Lan Qu
Yu-Lan Qu
XSXianbin Su
Xianbin Su
Ze-Guang HanZe-Guang Han
Ze-Guang Han
The conserved zona pellucida (ZP) domain is found in hundreds of extracellular proteins that are expressed in various organs and play a variety of roles as structural components, receptors and tumor suppressors. A liver-specific zona pellucida domain-containing protein (LZP), also named OIT3, has been shown to be mainly expressed in human and mouse hepatocytes; however, the physiological function of LZP in the liver remains unclear. Here, we show thatLzpdeletion inhibited very low-density lipoprotein (VLDL) secretion, leading to hepatic TG accumulation and lower serum TG levels in mice. The apolipoprotein B (apoB) levels were significantly decreased in the liver, serum, and VLDL particles of LZP-deficient mice. In the presence of LZP, which is localized to the endoplasmic reticulum (ER) and Golgi apparatus, the ER-associated degradation (ERAD) of apoB was attenuated; in contrast, in the absence of LZP, apoB was ubiquitinated by AMFR, a known E3 ubiquitin ligase specific for apoB, and was subsequently degraded, leading to lower hepatic apoB levels and inhibited VLDL secretion. Interestingly, hepatic LZP levels were elevated in mice challenged with a high-fat diet and humans with simple hepatic steatosis, suggesting that LZP contributes to the physiological regulation of hepatic TG homeostasis. In general, our data establish an essential role for LZP in hepatic TG transportation and VLDL secretion by preventing the AMFR-mediated ubiquitination and degradation of apoB and therefore provide insight into the molecular function of LZP in hepatic lipid metabolism.

29 May 2021 in Advanced Science
Verified
Journal Article
Open access
PDF file
ZZZhuangzhuang Zhang
Zhuangzhuang Zhang
LCLijun Cheng
Lijun Cheng
QZQiongsi Zhang
Qiongsi Zhang
YKYifan Kong
Yifan Kong
DHDaheng He
Daheng He
XLXiaoqi Liu
Xiaoqi Liu
Because there is no effective treatment for late‐stage prostate cancer (PCa) at this moment, identifying novel targets for therapy of advanced PCa is urgently needed. A new network‐based systems biology approach, XDeath, is developed to detect crosstalk of signaling pathways associated with PCa progression. This unique integrated network merges gene causal regulation networks and protein‐protein interactions to identify novel co‐targets for PCa treatment. The results show that polo‐like kinase 1 (Plk1) and DNA methyltransferase 3A (DNMT3a)‐related signaling pathways are robustly enhanced during PCa progression and together they regulate autophagy as a common death mode. Mechanistically, it is shown that Plk1 phosphorylation of DNMT3a leads to its degradation in mitosis and that DNMT3a represses Plk1 transcription to inhibit autophagy in interphase, suggesting a negative feedback loop between these two proteins. Finally, a combination of the DNMT inhibitor 5‐Aza‐2’‐deoxycytidine (5‐Aza) with inhibition of Plk1 suppresses PCa synergistically.

20 July 2023 in The Prostate
Verified
Journal Article
Closed access
ZZZhuangzhuang Zhang
Zhuangzhuang Zhang
XWXinyi Wang
Xinyi Wang
MKMiyeong Kim
Miyeong Kim
DHDaheng He
Daheng He
CWChi Wang
Chi Wang
XLXiaoqi Liu
Xiaoqi Liu


3 April 2023
Verified
Other
Open access
YKYifan Kong
Yifan Kong
YZYanquan Zhang
Yanquan Zhang
FMFengyi Mao
Fengyi Mao
ZZZhuangzhuang Zhang
Zhuangzhuang Zhang
ZLZhiguo Li
Zhiguo Li
XLXiaoqi Liu
Xiaoqi Liu
AR expressions in various cell lines & combinational effects on PC3 and DU145